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Abstract
Autocrine priming of cells by small quantities of constitutively produced type I interferon (IFN) is a well-known
phenomenon. In the absence of type I IFN priming, cells display attenuated responses to other cytokines, such as anti-viral
protection in response to IFNc. This phenomenon was proposed to be because IFNa/b receptor1 (IFNAR1) is a component
of the IFNc receptor (IFNGR), but our new data are more consistent with a previously proposed model indicating that
regulated expression of STAT1 may also play a critical role in the priming process. Initially, we noticed that DNA binding
activity of STAT1 was attenuated in c-Jun
2/2 fibroblasts because they expressed lower levels of STAT1 than wild-type cells.
However, expression of STAT1 was rescued by culturing c-Jun
2/2 fibroblasts in media conditioned by wild-type fibroblasts
suggesting they secreted a STAT1-inducing factor. The STAT1-inducing factor in fibroblast-conditioned media was IFNb,a si t
was inhibited by antibodies to IFNAR1, or when IFNb expression was knocked down in wild-type cells. IFNAR1
2/2 fibroblasts,
which cannot respond to this priming, also expressed reduced levels of STAT1, which correlated with their poor responses
to IFNc. The lack of priming in IFNAR1
2/2 fibroblasts was compensated by over-expression of STAT1, which rescued
molecular responses to IFNc and restored the ability of IFNc to induce protective anti-viral immunity. This study provides a
comprehensive description of the molecular events involved in priming by type I IFN. Adding to the previous working
model that proposed an interaction between type I and II IFN receptors, our work and that of others demonstrates that type
I IFN primes IFNc-mediated immune responses by regulating expression of STAT1. This may also explain how type I IFN can
additionally prime cells to respond to a range of other cytokines that use STAT1 (e.g., IL-6, M-CSF, IL-10) and suggests a
potential mechanism for the changing levels of STAT1 expression observed during viral infection.
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Introduction
Although type I and type II interferons (IFNs) have distinct roles
in immune responses, there is substantial overlap between the
genes and cellular responses they regulate. It has been known for
some time that many cells secrete small priming quantities of type I
IFNs that facilitate more potent responses to subsequent stimuli
[1–3]. Moreover, cellular responses to CSF-1 or IFNc can be
affected by neutralizing type I IFN antibodies or knockout of type I
IFN-Receptors (IFNAR) [2,4,5]. Notably, the protective anti-viral
effects of IFNc were much less potent in IFNAR1
2/2 than wild-type
fibroblasts which appeared to be caused by a lack of type I IFN
priming [4,5]. The molecular events that underpin these priming
events have not been fully characterized, although it has been
proposed that type I and II IFNs shared receptor components [5].
However, as the majority of responses to type I and II IFNs
require the expression of the STAT1 transcription factor [6], this
is also a possible point of crosstalk between them.
STAT1 is a key mediator of cytokine-induced gene expression
as it is activated either as homo- or heterodimer with other STATs
by many cytokines including type I and type II IFNs, interleukin
(IL)-6 and IL-10. STAT1 activity is of particular importance to the
IFN system as STAT1
2/2 mice display many similar phenotypes
to mice lacking IFNAR1 or the IFN Receptor (IFNGR)1. In
particular, anti-viral, anti-mycobacterial, and anti-tumor responses
are compromised [6–9]. Induction of STAT1 expression is a
potential explanation for the priming activity of type I IFN
because it is an IFN-stimulated gene (ISG) itself [10–12] and its 59
promoter region contains an IRF/gamma activated sequence
(GAS) element bound by IFN-stimulated transcription factors
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of this factor available for activation by IFNc. Consistent with such
a hypothesis, low expression of STAT1 correlated with IFN-
resistance in melanoma samples when compared to surrounding
normal tissue [14].
In unstimulated cells, STAT1 resides in the cytoplasm as a
latent factor that is activated by a series of post-translational
modifications initiated when it is recruited to cytokine receptors
following receptor ligation [15]. At the receptor, STAT1 is
phosphorylated on tyrosine 701, by Janus family kinase (JAK)s,
which facilitates its dimerization either with other STAT1
molecules or other STAT proteins depending on the cytokine
receptor. In addition, STAT1 proteins are phosphorylated on
serine 727 prior to nuclear translocation which is essential for their
full transcriptional activity [16]. Conversely, STAT1 activity is
negatively regulated by phosphatases, SOCS proteins, and the
SUMO ligase Protein Inhibitor of Activated STAT (PIAS)1 [15].
Recently, in the course of our studies on IFNc-activated AP-1
DNA binding, we noticed that IFNc-induced GAS DNA binding
was suppressed in c-Jun
2/2 cells compared to wild-type cells [17]
and this correlated reduced levels of STAT1 in c-Jun
2/2 cells. The
level of STAT1 expression in c-Jun
2/2 murine embryonic
fibroblasts (MEFs) were restored to wild-type levels following
culture in media conditioned by wild-type fibroblasts suggesting
that c-Jun deficiency caused the disruption of an autocrine/
paracrine loop that regulated STAT1 expression. The STAT1-
inducing component of media conditioned by wild-type fibroblasts
was IFNb, because the activity could be blocked by neutralizing
antibodies directed against type I IFN and antibodies used were
raised against IFNAR and attenuated by targeted knockdown of
IFNb by RNA interference (RNAi). While c-Jun has been
demonstrated to co-operate with ATF-2, IRF-3, and NFkB for
virus-induced production of IFNb [18], to our knowledge our
studies are the first to demonstrate that c-Jun is necessary for basal
expression of low-level IFNb. Fibroblasts in which this autocrine/
paracrine loop was disrupted by the loss of components of type I
IFN receptors also express lower levels of STAT1. As many
biological functions of IFN require STAT1 [6,7], this suggested
that previous observations of attenuated responses to IFN in
IFNAR1
2/2 cells may be related to the reduced STAT1
expression that has been observed [19]. Consistent with this
hypothesis, restoring STAT1 expression in IFNAR1
2/2 fibroblasts
rescued IFNc-induced gene transcription and anti-viral properties.
In summary, this study provides evidence of an autocrine/
paracrine stimulatory loop that requires the expression of c-Jun,
IFNb, and IFNAR to regulate the expression of STAT1.
Importantly, this basal IFNb production occurs via a mechanism
distinct from the pathogen-stimulated IFNb production mediated
by IRF and NFkB pathways [18]. One model to explain crosstalk
between type I and II IFNs states that type I and II IFN-R
physically interact in a ligand-dependant manner, such that the
presence of type I IFNs is essential for a fully competent IFNc
response [5]. Herein, we demonstrated that attenuated IFNc-
mediated gene induction and an associated defective anti-viral
response to IFNc that is observed in IFNAR1-deficient cells can be
rescued by re-expressing STAT1 and is therefore independent of
IFNAR1. We propose that an alternative model to explain the
functional synergy between type I and II IFNs is based on the
regulated expression of STAT1 via c-Jun-mediated production of
basal levels of IFNb.
Results
STAT1 Expression Is Attenuated in c-Jun
2/2 MEFs
In the course of our studies of IFN-induced signaling and gene
expression, we performed elecrophoretic mobility shift assays
(EMSAs) assessing GAS binding species in nuclear extracts from
IFNc-stimulated wild-type and c-Jun
2/2 MEFs. A GAS binding
complex was detected in both wild-type and matched c-Jun
2/2
MEFs following 15–30 min of exposure to IFNc, however in the
absence of c-Jun, IFNc-induced GAS binding activity was
markedly attenuated (Figure 1A). The decrease in GAS binding
activity in c-Jun
2/2 MEFs was a consequence of reduced
expression of STAT1. Both STAT1 mRNA and protein were
,10-fold lower in c-Jun
2/2 MEFs compared to wild-type cells
(Figure 1B and C). However, expression of STATs was not
globally affected, as expression of STAT3, another GAS-binding
transcription factor, remained unchanged (Figure 1C). Reduced
STAT1 expression was not a clone-specific phenomenon as similar
results were obtained using an independently derived matched
pair of wild-type and c-Jun
2/2 MEFs (Figure S1).
c-Jun Maintains Levels of STAT1 Expression by
Stimulating Autocrine Production of a Soluble Factor
To determine if c-Jun could regulate STAT1 levels by inducing
the secretion of a soluble factor that acted in autocrine/paracrine
fashion to induce STAT1 expression, conditioned media from
wild-type or c-Jun
2/2 MEFs were cultured in (i) fresh media, (ii)
media conditioned by c-Jun
2/2 MEFs, or (iii) media conditioned
by wild-type MEFs. Cells were harvested after 16 h of culture in
conditioned media and STAT1 mRNA and protein expression was
assessed. Expression of STAT1 mRNA and protein was unaltered
in wild-type MEFs cultured in fresh media or conditioned media
from wild-type or c-Jun
2/2 MEFs (Figure 2A and B). In c-Jun
2/2
MEFs, basal expression of STAT1 was much lower than in wild-
type cells and was not increased when the cells were cultured in
either fresh media or conditioned media from c-Jun
2/2 MEFs
(Figure 2A and B). In contrast, when c-Jun
2/2 MEFs were
cultured in media conditioned by wild-type MEFs, STAT1 mRNA
and protein expression was induced almost to the levels observed
in wild-type cells (Figure 2A and B). These data confirmed that
fibroblasts secrete a c-Jun-dependent soluble factor that induces
STAT1 expression through an autocrine/paracrine feedback loop.
Author Summary
Cells of the immune system release interferons (IFNs) in
response to pathogens or tumor cells; these proteins
signal to other immune cells to initiate the body’s defense
mechanisms. The two classes of IFNs—types I and II—have
different receptors and distinct effects on the cells;
however, there is ‘‘crosstalk’’ between them. In particular,
small quantities of type I IFN can ‘‘prime’’ cells to produce
a robust response to type II IFN. In this paper, we provide
evidence to explain the molecular basis of this crosstalk.
We show that continuous expression of the transcriptional
activator c-Jun is responsible for producing basal, priming
levels of a type I IFN; this signals to immune cells with the
type I IFN receptor (IFNAR1) to maintain expression of
STAT1 inside these cells. STAT1 is a key factor for immune
cell responses to type II IFN. Thus, signaling by low levels
of type I IFN primes the cells with sufficient STAT1 to
respond robustly to a subsequent type II IFN signal. This
work provides an alternative explanation of the priming
phenomenon to a previous proposal that the ligand-
bound type I receptor, IFNAR1, acts as a component of the
type II IFN receptor.
c-Jun promotes IFNc responses via IFNb and STAT1
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of STAT1
Type I IFN is constitutively secreted from unstimulated fibroblasts
and can induce STAT1 expression [10]. To determine if type I IFN
was the STAT1-inducing active component of fibroblast condi-
tioned media, c-Jun
2/2 MEFs were cultured in either fresh or
conditioned media from wild-type cells in the presence of a type I
IFN blocking antibody [20]. STAT1 expression was increased in
c-Jun
2/2 MEFs cultured in conditioned media from wild-type cells
in the presence of control antibodies (Figure 3A) and this enhanced
expression was entirely blocked by the presence of type I IFN
neutralizing antibodies used at concentrations capable of neutral-
izing ,5 IU/mL IFNb. Additional studies (Figure 3B and C)
revealed that the STAT1-inducing activity of wild-type-conditioned
media was almost ablated by a blocking mAb raised against
IFNAR1 [21]. Together, these data demonstrate that type I IFN is
a component of conditioned media from wild-type cells that is
necessary for the rescue of STAT1 expression in c-Jun
2/2 cells.
It has been reported that STAT1 levels are diminished in
IFNb
2/2 cells [22] indicating that IFNb could be the key
component of the conditioned media from wild-type cells shown
to induce expression of STAT1 in c-Jun
2/2 MEFs. Treatment of
c-Jun
2/2 MEFs with doses as low as 1 IU/mL IFNb induced
STAT1 mRNA and doses between 5 and 10 IU/mL were
sufficient to restore STAT1 mRNA and protein expression to levels
seen in wild-type cells (Figure S2A and B). STAT1 mRNA levels
were slightly increased in wild-type MEFs treated with IFNb
(Figure S2C), which is consistent with studies demonstrating that
STAT1 expression is induced in fibosarcoma cell lines treated with
IFNa or b [12] and in splenic leukocytes where STAT1 levels were
increased following virus infection in a type I IFN-dependent
manner [11]. Comparison of the levels of expression of IFNb
mRNA in wild-type and c-Jun
2/2 cells revealed that c-Jun
2/2
MEFs expressed ,50% of the wild-type levels of IFNb mRNA
(Figure 4A). AP-1 sites are known to be important for inducible
expression of IFNb [23], but little is known of what regulates
Figure 1. STAT1 DNA binding and expression is attenuated in c-Jun-deficient MEFs. (A) EMSAs were performed using radiolabeled
oligonucleotides containing a GAS consensus sequence, and nuclear extracts from wild-type or c-Jun
2/2 MEFs treated with 100 IU/mL IFNc for
indicated times. (B) RNA was extracted from wild-type or c-Jun
2/2 MEFs, cDNA synthesized, and qRT-PCR performed with primers complementary to
murine STAT1. Histograms represent mean and error bars the SEM of four independent experiments and are expressed relative to the levels detected
in wild-type cells (* p,0.05). (C) SDS-PAGE and Western blotting with antibodies against STAT1 and STAT3 were performed using whole cell extracts
from wild-type or c-Jun
2/2 MEFs. As a control, the expression of a-tubulin was also tested by Western blot.
doi:10.1371/journal.pbio.1000361.g001
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fibroblasts. Chromatin immunoprecipitation (ChIP) assays on
unstimulated wild-type and c-Jun
2/2 MEFs demonstrated a .2-
fold increase in c-Jun bound to the murine IFNb promoter when
compared to Ig control samples (Figure 4B). Together, these data
imply that expression of c-Jun and subsequent occupation of the
IFNb promoter by c-Jun is required for basal secretion of IFNb.
To determine if IFNb was the type I IFN necessary to maintain
STAT1 expression, we used RNAi to knock down IFNb in wild-type
MEFs (Figure 4C) and assessed the ability of conditioned media
from these cells to induce the expression of STAT1 mRNA in c-
Jun
2/2 MEFs. As expected, STAT1 mRNA levels were greater
when c-Jun
2/2 MEFs were cultured in conditioned media from
wild-type MEFs or from MEFs expressing a control knockdown
vector than if these cells were cultured in fresh media (Figure 4D).
In contrast, the ability of conditioned media from wild-type cells
with RNAi-mediated knockdown of IFNb to induce STAT1
expression in c-Jun
2/2 MEFs was significantly reduced
(Figure 4D). These data confirm that IFNb is expressed by
unstimulated wild-type fibroblasts and is necessary for the
maintenance of STAT1 expression.
IFNAR-Deficient Cells Express Reduced Levels of STAT1
As disruption of autocrine/paracrine stimulation by IFNb
affected the level of STAT1 expression in c-Jun
2/2 MEFs, we
predicted that cells lacking either chain of the type I IFN receptor
would also express less STAT1 than wild-type cells. Primary MEFs
(Figure 5A) and splenocytes (Figure 5B) from either IFNAR1
2/2 or
IFNAR2
2/2 (unpublished data) mice expressed significantly lower
levels of STAT1 than wild-type cells. We extended these studies to
compare the expression of STAT1 across multiple tissues in wild-
type versus IFNAR1
2/2 mice. As shown in Figure 5C, the levels of
STAT1 were consistently reduced in all tissues from IFNAR1
2/2
mice compared to their wild-type counterparts, suggesting this
defect may have broad physiological importance. Interestingly
expression of STAT2 was also reduced in IFNAR11
2/2 MEFs
while the levels of STAT3 were unaffected by knockout of the type
I IFN receptor (Figure S3A).
Our model predicted that, unlike c-Jun deficiency that affected
production of an autocrine stimulus, IFNAR1 deficiency affects
responses to the autocrine stimulus. In support of this model, wild-
type-conditioned media was able to rescue the expression of
STAT1 in c-Jun
2/2 MEFs, but in IFNAR1
2/2 MEFs STAT1
expression was unaffected by culture in wild-type-conditioned
media (Figure S3B). These data support the existence of an
autocrine loop involving IFNb that regulates basal STAT1
expression levels and suggest that defects in any part of this loop
are likely to affect the expression of STAT1.
Re-Expression of STAT1 in IFNAR-Deficient Cells Restores
IFNc Signaling and Gene Expression
STAT1 is important for not only IFNa/b signaling but also the
signaling of several other cytokines, including IFNc [15]. The
expression of approximately two-thirds of IFNc-induced genes
is dependent upon STAT1 expression, however not all IFNc-
mediated biological responses are entirely dependent on STAT1
expression [17,24]. It has previously been reported that IFNAR1
2/2
cells are refractory to IFNc treatment due to the proposed
Figure 2. c-Jun is necessary for constitutive IFNb secretion and subsequent maintenance of STAT1 expression. Wild-type or c-Jun
2/2
MEFs were cultured in fresh media (Fresh) or conditioned media from either c-Jun
2/2 (c-Jun
2/2 CM) or wild-type (wild-type CM) MEFs for 16 h. Cells
were harvested, and (A) RNA was extracted and STAT1 mRNA expression assessed by qRT-PCR. Histograms represent mean and error bars the SEM of
three independent experiments and are expressed relative to the levels detected in wild-type cells cultured in fresh media (* p,0.05 between
indicated samples). (B) Whole cell lysates from treated cells were analyzed by SDS-PAGE and Western blot probed with an antibody specific for STAT1
and a-tubulin to confirm equivalent protein loading.
doi:10.1371/journal.pbio.1000361.g002
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decreased expression of STAT1 may confer the observed decrease
of IFNc-mediated responses in IFNAR1
2/2 cells, STAT1 levels
were restored in these cells by retroviral transduction (Figure 6A).
GAS binding activity was assessed by EMSA using nuclear extracts
from IFNc-treated wild-type MEFs, IFNAR1
2/2 MEFs, and
IFNAR1
2/2 MEFs reconstituted with empty vector (IFNAR1
2/2
MSCV)o rS T A T 1( IFNAR1
2/2 HA-STAT1). Consistent with
previous studies [5,25], IFNc induced less GAS binding in
IFNAR1
2/2 cells than wild-type cells (Figure 6B). This low level of
GAS binding was also observed in cells transduced with empty
vector but was rescued in cells reconstituted with HA-STAT1a.
These data demonstrated that the reduced GAS binding observed in
IFNAR1
2/2 cells was caused by reduced STAT1 expression rather
than being a direct consequence of IFNAR1 deficiency.
Previous studies demonstrated that IFNc-induced gene expres-
sion was attenuated in IFNAR1
2/2 cells [5]. We therefore assessed
the impact of re-expression of STAT1a in IFNAR1
2/2 cells upon
the IFNc-induced expression of genes such as b-2-microglobulin and
SOCS3 that require STAT1 expression [26]. Both genes were
induced in response to IFNc in wild-type cells, although with
differing kinetic profiles, but induction was weak or absent in
IFNAR1
2/2 cells. IFNc-induced expression of both b-2-micro-
globulin and SOCS3 was restored in cells that re-expressed HA-
STAT1a, but not in cells transduced with an empty vector
(Figure 6C, D). Similar results were observed when other IFNc-
responsive genes were tested (Figure S4).
Expression of STAT1 in IFNAR-Deficient Cells Restores
Their Protective Anti-Viral Response Following Treatment
with IFNc
In order to determine whether the reduced levels of STAT1 in
IFNAR1
2/2 cells could affect biological responses to IFNc,w e
investigated whether re-expression of STAT1 in IFNAR1
2/2 cells
impacted upon the ability of IFNc to protect them against
infection by the cytopathic virus murine encephalomyocarditis
virus (EMCV). Wild-type, IFNAR1
2/2, IFNAR1
2/2 MSCV, and
IFNAR1
2/2 HA-STAT1 MEFs were infected with a dose of virus
sufficient to induce 100% lysis of wild-type MEFs in the presence or
absence of various doses of IFNc, and the cytopathic effects were
determined by assessing cell viability after 24 h. As was shown
previously [5], the ability of IFNc to protect cells from EMCV-
mediated lysis was significantly reduced in IFNAR1
2/2 MEFs
when compared to wild-type MEFs at most doses of IFNc and the
concentration of IFNc (500 IU/ml) required to provide 80%
protection from the virus for IFNAR1
2/2 cells was much greater
than that required to provide a similar level of protection for wild-
type cells (10 IU/ml). The response of IFNAR1
2/2 MEFs
transduced with empty vector to IFNc was not significantly
different from the untransduced IFNAR1
2/2 MEFs at any dose of
IFNc and the concentration of IFNc required to provide 80%
protection (450 IU/ml) was of a similar order of magnitude
(Figure 7). In contrast, protection from virus-induced lysis was
significantly enhanced in IFNAR1
2/2 HA-STAT1 MEFs at most
doses of IFNc. These data provide direct evidence that the
attenuated protective anti-viral responses to IFNc observed in
IFNAR1
2/2 cells is a consequence of reduced STAT1 expression.
Discussion
Herein we demonstrate that c-Jun is essential for the constitutive
production of small quantities of IFNb that initiates autocrine or
paracrine feedback loops required to maintain the expression of
STAT1 (Figure 8). This system was disrupted either by c-Jun
Figure 3. Antibodies that block type I IFN function modulate
STAT1 expression. c-Jun
2/2 MEFs were cultured in fresh media or
media conditioned by wild-type MEFs for 16 h. RNA was extracted and
STAT1 mRNA expression assessed by qRT-PCR. (A) Conditioned media
were supplemented with control antibody (Ctrl Ab) or type I IFN
neutralizing antibody (IFN Ab). Histograms represent the mean and error
bars the SEM of four independent experiments. (B) Conditioned media
were supplemented with control antibody (Ctrl) or blocking antibody to
IFNAR1 (IFNAR1 Ab). Histograms represent the mean and error bars the
SEM of five independent experiments. In each case STAT1 levels are
expressedrelativetothelevelsdetectedinc-Jun
2/2cellsculturedinfresh
media. (* p,0.05 between indicated samples). (C) Wild-type MEFs were
cultured for various times in media containing antibodies to IFNAR1 or a
control antibody for 96 h. At each time point, cells were harvested, whole
cell extracts prepared, and STAT1 expression assessed by Western blot.
Tubulin expression was assessed as a loading control.
doi:10.1371/journal.pbio.1000361.g003
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deficiency, which affects the ability of cells to respond to the
autocrine stimulus. Consistent with our data, others found that
cells lacking IFNb also express much lower levels of STAT1 [22]
and virus-mediated induction of STAT1 is dependent on type I
IFN signaling [11]. As IFNc signaling is attenuated when the
autocrine stimulus is blocked (Figure 8) but restored by adding
back STAT1, it appears the level of STAT1 expressed by the cell
determines the response of the cell to other cytokines. These results
suggested the ability of IFNc to induce a protective anti-viral state
was due to the type I IFN-mediated maintenance of STAT1
expression rather than the recruitment of IFNAR1 into the IFNcR
complex as has been previously proposed [5]. These findings
define a novel mechanism through which STAT1-mediated
signals can be regulated and highlight the importance of crosstalk
between type I and II IFNs for anti-viral immunity.
It has been known for some time that, as well as being
produced in large quantities following viral infections, cells can
secrete low levels of type I IFN constitutively [1,2,27]. Virus-
induced activation of the IFNb enhanceasome is one of the best-
characterized transcriptional modules [18,23]. Viral activation of
the IFNb promoter involves the binding of NFkB, IRF3, and
ATF2/c-Jun complexes to a series of DNA elements termed
PRD I-IV [23]. In this setting, c-Jun binds to PRD IV of the
promoter and facilitates co-operative binding of the other
factors. Removing PRD IV from the promoter, or even reversing
Figure 4. c-Jun binds to the IFNb promoter and is required to maintain its expression in unstimulated cells. (A) RNA from wild-type and
c-Jun
2/2 MEFs were assayed for IFNb expression by qRT-PCR. Histograms represent mean and error bars the SEM of three independent experiments
and are expressed relative to the levels detected in wild-type cells (arbitrarily set as one). (B) ChIP assays were performed using chromatin from wild-
type MEFs using an anti c-Jun antibody or an isotype control antibody. Immuno-precipitated chromatin was assessed for enrichment of the IFNb
promoter by qRT-PCR using primers flanking PRD IV. Loading of c-Jun on PRD IV was calculated relative to isotype control. Histograms represent the
mean and error bars the SEM of three independent experiments (* p,0.05 between indicated samples). (C) RNA was prepared from wild-type MEFs
infected with recombinant lentivirus encoding microRNAs (miRs) targeting the IFNb gene or a control miR. Expression of IFNb was assessed by qRT-
PCR. Histograms represent the mean and SEM of three independent experiments (* p,0.05 between indicated samples). (D) c-Jun
2/2 MEFs were
treated with conditioned media from untransduced wild-type MEFs and MEFs transduced with lentivirus encoding either miRs targeting the IFNb
gene or a non-silencing miR or with fresh media. After 24 h, cells were harvested, RNA prepared, and STAT1 expression assessed by qRT-PCR.
Histograms represent the mean and error bars the SEM of five independent experiments (* p,0.05 between indicated samples).
doi:10.1371/journal.pbio.1000361.g004
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of the promoter [23], suggesting the role of c-Jun is critical in the
context of viral infection. In contrast, little is known of the
molecular mechanisms of constitutive type I IFN production.
Our study indicates that PRD IV of the IFNb promoter is
occupied by c-Jun even in ‘‘resting’’ cultured cells (Figure 4B).
This requirement for c-Jun explains why we found that
constitutive IFNb production and hence the expression of
STAT1 was attenuated in c-Jun
2/2 cells. In addition to
regulating basal expression of IFNb, we have recently demon-
Figure 5. STAT expression in primary IFNAR-deficient cells. Wild-type and strain matched IFNAR1
2/2 mice were sacrificed and RNA from (A)
primary MEFs, (B) splenocytes, or (C) various indicated tissues was extracted, cDNA synthesized, and STAT1 mRNA expression assessed by qRT-PCR.
STAT1 expression was normalized to untreated wild-type cells. Histograms show the mean of three independent experiments and error bars SEM (*
p,0.05 between indicated samples).
doi:10.1371/journal.pbio.1000361.g005
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2/2 MEFs rescues their IFNc responsiveness. (A) Protein extracts from wild-type
MEFs, IFNAR1
2/2 MEFs, and IFNAR1
2/2 MEFs transduced with empty vector (IFNAR1
2/2 MSCV) or IFNAR1
2/2 MEFs transduced with HA tagged
STAT1a (IFNAR1
2/2 STAT1) were subjected to SDS-PAGE and probed with an antibody specific to STAT1,and membranes were stripped and re-
probed with antibodies specific to hsp70 as a loading control. (B) EMSAs were performed using radiolabeled oligonucleotides containing a GAS
consensus sequence, and nuclear extracts from wild-type MEFs, IFNAR1
2/2 MEFs, IFNAR1
2/2 MEFs transduced with empty vector (IFNAR1
2/2 MSCV),
or IFNAR1
2/2 MEFs transduced with HA tagged STAT1a (IFNAR1
2/2 STAT1) treated in the presence or absence of 100 IU/mL IFNc. (C, D) Wild-type
MEFs, IFNAR1
2/2 MEFs, and IFNAR1
2/2 MEFs transduced with empty vector (IFNAR1
2/2 MSCV) or IFNAR1
2/2 MEFs transduced with HA-tagged
STAT1a (IFNAR1
2/2 STAT1) were treated with 100 IU/mL IFNc for 0, 1, or 6 h. RNA was extracted, cDNA synthesized, and qRT-PCR performed with
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also play a direct role in regulating the expression of a subset of
IFNc-responsive genes (ISGs) [17]. Indeed we identified ISGs
that were dependent on c-Jun for induction by IFNc,o t h e r st h a t
required STAT1, and others that required both c-Jun and
STAT1 for increased expression following treatment with IFNc
[17]. These results, coupled with the functional data provided
herein, highlight the complex molecular interplay between c-Jun
and canonical mediators of type I and II IFN signaling such as
STAT1 in regulating a comprehensive response to IFN
treatment.
Takaoka and colleagues previously demonstrated the impor-
tance of IFNb in the production of an IFNc-mediated anti-viral
response [5]. In that paper the authors showed that IFNb
2/2
MEFs were defective in mounting an IFNc-induced antiviral
response. These data mirror what we have demonstrated herein
where we show that IFNAR1
2/2 MEFs show a similar defect in
mounting an IFNc-induced antiviral response. However, we
showed that restoring STAT1 expression in IFNAR1
2/2 cells
significantly rescued the ability of IFNc to protect cells against
EMCV, suggesting that regulating the levels of STAT1
expression through the autocrine loop may play an important
role in responses to this challenge. The ability of type I and II
IFNs to co-operate, for example, in treatment of melanoma tissue
[28] or priming of macrophage cytotoxicity [29] has long been
recognized. Interestingly, at a cellular level, IFNAR1
2/2 cells
were known to have an anomalously poor response to IFNc with
respect to induction of GAS DNA binding, induction of gene
expression, and protection against the cytopathic effects of
EMCV [4,5,25]. IFNc function is not entirely compromised in
IFNAR1
2/2 animals because IFNGR1
2/2 mice have distinct
phenotypic differences from IFNAR1
2/2 mice [30]. Inhibiting
autocrine priming by type I IFN does not only affect signaling by
IFNc. Therefore its is not surprising that IL-6 signaling [31] and
CSF-1 signaling are affected by inhibiting priming by type I IFN
[2] and that signals induced by IL-10 can be affected by priming
with IFNs [32].
It was proposed that the ligand-bound IFNAR1 chain acts as a
component of the IFNGR and promotes recruitment of STAT1 to
the IFNGR because IFN receptors are clustered within caveolar
membrane fractions to facilitate their association [5]. Such a
hypothesis is inconsistent with mapping of the docking site of
STAT1 to the IFNAR2 chain of the type I IFN-R rather than the
IFNAR1 as specified by the shared receptor model [33]. We
demonstrated herein that IFNAR1
2/2 cells express lower basal
levels of STAT1 relative to wild-type controls (Figure 5), and as
STAT1 is a critical mediator of IFN signaling, this is an alternative
reason why these cells may lack sensitivity to IFNc. Our model not
primers specific for b-2-microglobulin and SOCS3. mRNA levels are expressed relative to those of wild-type C57/BL6 (B6) splenocytes. Histograms
represent the mean and error bars the standard error of four independent experiments. (* p,0.05 for samples that were significantly induced).
doi:10.1371/journal.pbio.1000361.g006
Figure 7. Restoration of STAT1a expression in IFNAR1
2/2 MEFs rescues the ability of IFNc to protect cells from cytopathic virus.
Wild-type MEFs, IFNAR1
2/2 MEFs, and IFNAR1
2/2 MEFs transduced with vector (IFNAR1
2/2 MSCV)o rIFNAR1
2/2 MEFs transduced with HA-tagged
STAT1a (IFNAR1
2/2 STAT1) were infected with EMCV (0.1 moi) in the presence or absence of various doses of IFNc. After 24 h, cells were stained with
crystal violet and viability assessed by measuring OD550 of the solubilized stain. The effect of IFNc was determined by comparison of OD550 with
samples of known viability. Data points are the mean and error bars represent standard error from three independent experiments. (* p,0.05
between wild-type and IFNAR1
2/2 ** p,0.05 between wild-type and IFNAR1
2/2).
doi:10.1371/journal.pbio.1000361.g007
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2/2 cells for
an anti-viral response and the rescue of IFNc function in
IFNAR1
2/2 cells by STAT1a expression but also the attenuated
responses to other cytokines, such as IL-6 and CSF-1, observed in
IFNAR1
2/2 cells [2,31] and predicts they may also be rescued by
expression of STAT1. As IFNc function was not entirely
recovered following re-expression of STAT1 in IFNAR
2/2 cells,
we cannot exclude that the shared receptor mechanism makes a
contribution, but there are other reasons why reconstitution of
STAT1 may not have fully rescued IFNc function. These include
the absence of other as yet unidentified signal transducing proteins
from cells of this genotype.
The level of STAT1 expression in cells can have functional
consequenceswithrespect toimmuneresponses. Inresponsetoviral
infection, Ag-specific CD8
+ T cellsexpress peak levelsof STAT1for
a shorter period of time than CD4
+ cells [34]. This decreased
sensitivitytoIFN-inducedgrowthinhibitionallowsexpansionofAg-
specific CD8
+ cells while the proliferation of cells with higher
STAT1 is inhibited [34]. The relative amounts of different STATs
can also affect the biological responses to cytokines. For example
STAT1:3 and STAT1:4 ratios have been shown to alter cellular
responses, and thus regulating the levels of these transcription
factors will affect the outcome of immune responses [11,35].
Our previous studies revealed that loss of IFN signaling
abrogated the immune-mediated neo-natal lethality of SOCS1
2/2
deficiency [36], and more recently we discovered that deleting
IFNAR1 also rescued this pathology [37] to a level equivalent to
SOCS1
2/2 IFN
+/2. Although SOCS1 directly regulated type I
IFN signaling, another reason why IFNAR1 deficiency can protect
SOCS1
2/2 animals may be the similarities and crosstalk between
type I and II IFN signaling pathways. These data highlight the
patho-physiological importance and mechanism of crosstalk
between type I and II IFN that are important considerations in
understanding the contributions of individual cytokines to host
defense and in their therapeutic targeting.
Materials and Methods
Cells and Reagents
c-Jun
2/2, IFNAR1
2/2 [38], IFNAR2
2/2 [39], and wild-type
matched MEFs were derived from embryos and either used as
early passage primary MEFs or immortalized by the ‘‘3T3’’
method. IFNAR1
2/2 MEFs were transduced with Murine stem
cell leukemia virus supernatants encoding GFP alone or cDNA
encoding HA-tagged STAT1 (generous gift from Thomas Decker).
Supernatants were produced by transient transfection of PhoenixE
cells with MSCV vector by calcium phosphate precipitation using
standard methods.
c-Jun
2/2 MEFs were transduced with lentiviral supernatants
encoding miR sequences targeting IFNb (Open Biosystems,
Huntsville, AL, USA; product numbers: RMM4431-98755134,
RHS4346). Supernatants were produced by transient transfection
of 293T cells with pGIPZ vector using Lentiphos HT kit
(Clontech, Mountain View, CA, USA) according to the manufac-
turer’s instructions.
Cells were cultured in DMEM supplemented with 5% foetal
bovine serum (JRH Biosciences, Lenexa, KS, USA) and 2 mM L-
Glutamine (JRH Biosciences, Lenexa, KS, USA). All tissue culture
reagents were certified sterile and free of Mycoplasma and
pyrogens. Antibodies for the following targets were used: STAT1
(BD Biosciences Franklin Lakes, NJ, USA), STAT3 (Santa Cruz
Biotech, Santa Cruz, CA, USA), HA (Cell Signaling Technology,
Beverly, MA, USA), c-Jun (Santa Cruz Biotech, Santa Cruz, CA,
USA), a-tubulin (Sigma Chemical Co., St. Louis, MO, USA), and
hsp70 (Clone N6 was a kind gift of Dr. Robin Anderson; Peter
MacCallum Cancer Centre, Melbourne, Australia). Neutralizing
anti type I IFN [20] and anti-IFNAR1 were described previously
[40]. HRP-conjugated secondary antibodies were purchased from
Dako (Glostrup, Denmark).
Production of Conditioned Media
3610
6 MEFs were cultured in 175 cm
2 tissue culture flasks in
20 mL media for 3 d. Supernatant was collected, cell debris
removed by centrifugation (670 g, 4 min), sterilized using a
0.22 mM filter, and stored at 4uC.
SDS-PAGE and Western Blotting
Western blotting was performed as previously described [17].
Briefly, cells were washed, resuspended in whole cell lysis buffer
(50 mM Tris-HCl pH 8, 0.1% Triton X-100, 150 mM NaCl,
0.1 mM EDTA, 0.1 mM EGTA, 10% glycerol, 1 mg/mL aprotinin,
0.5 mg/mL leupeptin, and 0.2 mM PMSF), and after (4uC1 0m i n )
lysates were cleared by centrifugation. Proteins were separated by
SDS-PAGE, transferred to immobilon P membranes (Millipore),
and probed with specific antibodies. Secondary antibodies were
conjugated to horseradish peroxidase and images were visualized by
chemiluminescence (ECL, GE Healthcare, Bucks, UK).
Nuclear Extraction and EMSA
Nuclear extractions and EMSAs were performed as previously
described [17]. Briefly, cells were resuspended in hypotonic lysis
Figure 8. STAT1 levels are regulated by autocrine/paracrine
stimulation by type I IFN. c-Jun regulates secretion of small amounts
of type I IFN, which then stimulate adjacent cells and induce the
expression of STAT1. The level of STAT1 that is expressed by a cell
dictates how it responds to other stimuli, such as IFNc, and other
cytokines.
doi:10.1371/journal.pbio.1000361.g008
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protease inhibitors) (4uC, 5 min), NP-40 was added to a final
concentration of 0.25%, and the nuclei isolated by centrifugation
(2,000 g, 10 min). Nuclei were resuspended in hypertonic lysis
buffer (5 mM HEPES pH 8, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5
M NaCl, 25% glycerol, and protease inhibitors) (4uC, 1 h). For
binding reactions 5–10 mg of nuclear lysate was incubated (4uC, 30
min) with 5610
4 cpm T4 PNK-
32P-labeled oligonucleotides in
binding buffer (20 mM Tris/HCl pH 8, 6 mM KCl, 2 mM
MgCl2, 12% Glycerol, 5 mM DTT, 2.5 mg polydI.dC.polydI.dC,
and 0.05% NP-40). Complexes were separated by 5% native
PAGE, and gels were dried and visualized by autoradiography on
X-ray film (Kodak). The sequence of the GAS oligonucleotide 59-
TAGGGATTTACGGGAAATTGATGAAGCTGATC-39 was
derived from the FccRI promoter; the AP-1 oligonucleotides were
described previously [17].
Quantitative Real Time PCR
RNA was extracted using Trizol (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. cDNA was
synthesized from 2 mg RNA using superscript III (Invitrogen,
Carlsbad, CA, USA) as per the manufacturer’s instructions. The
abundance of specific genes in the samples was quantitated using
the SYBR Green dye detection method (Applied Biosystems,
Foster City, CA, USA). Primers to murine GBP-1 (59-TGT-
GGTTGCTGGATGAGCAGAGTA-39;5 9-AAGGAAACACA-
GTAGGCTGGAGCA-39), SOCS3 (59-CCTTCAGCTCCAAAA-
GCGAG-39;5 9-GCTCTCCTGCAGCTTGCG-39), and IFNb
(59-AGCTCCAAGAAAGGACGAACAT-39;5 9-GCCCTGTAG-
GTGAGGTTGATCT-39) were designed using Primer Express 2
software (Applied Biosystems, Foster City, CA, USA). Primers to
murine STAT1 gene (59-CGCGCATGCAAGTGGCATATA-
ACT-39;5 9-AAGCTCGAACCACTGTGACATCCT-39) were
designed using PrimerQuest software (Integrated DNA Technol-
ogies). Primers to ribosomal L32 (59-TTCCTGGTCCACAA-
CGTCAAG-39;5 9-TGTGAGCGATCTCGGCAC-39) were as
previously described [17]. Threshold cycle numbers (Ct) were
measured in the exponential phase for all samples. Relative
abundance of sample genes was calculated using the DDCt method
relative to the L32 control gene [17]. mRNA abundance was
normalized to the untreated samples of each genotype.
ChIP
ChIP assays were performed as described previously [41] using
5 mg of anti c-Jun or rabbit IgG control antibodies. The
abundance of specific sequences in ChIP samples was quantitated
using the SYBR Green dye detection method (Applied Biosystems,
Warrington, UK). Primers used for PCR reactions were mIFN
PRDIV (59-ATTCCTCTGAGGCAGAAAGGACCA; 59-GCA-
AGATGAGGCAAAGGCTGTCAA) and were designed using
Primer Express 2 software. Threshold cycle values (Ct) were
measured in the exponential phase, and promoter occupancy was
calculated using the formula 2
(Ct Ig 2 Ct c-Jun).
Statistical Analysis
Statistical significance was tested using one-way ANOVA
testing with OriginLab 7.5 software (Northampton, MA, USA)
or Prism Software Graphpad (La Jolla, CA, USA).
Viral Protection Assays
10
3 cells of each genotype were plated in duplicate wells in a 96
well plate and allowed to adhere. Media was replaced with fresh
media containing murine EMCV (M.O.I of 0.1) and various
concentrations of IFNc (0–1,000 IU/mL) and cultured for 16 h.
As controls, cells were cultured in fresh media alone (100%
survival) or with EMCV alone (0% survival). Cells were washed in
PBS, formalin fixed (10 min at RT), washed (twice with PBS), and
stained in 0.5% Crystal Violet/20% methanol. Stained cells were
extensively washed, crystal violet was solubilized in 10% acetic
acid, and OD550 nm was recorded. Viability was calculated by
comparison against a standard curve.
Supporting Information
Figure S1 STAT1 expression is decreased in c-Jun
knockout cells. SDS-PAGE and Western blotting with antibodies
against STAT1 was performed using whole cell extracts from an
independently derived set of wild-type or c-Jun
2/2 MEFs. As a
control, the expression of a-tubulin was also tested by Western blot.
Found at: doi:10.1371/journal.pbio.1000361.s001 (0.35 MB TIF)
Figure S2 IFNb regulates the expression of STAT1. (A)
c-Jun
2/2 MEFs were treated with various doses of IFNb for 24 h,
RNA was isolated, and expression of STAT1 was assessed by
qRT-PCR. STAT1 expression in untreated wild-type MEFs was
also assessed as a control. Histograms represent mean and error
bars the SEM of three independent experiments and are expressed
relative to the levels detected in c-Jun
2/2 cells (arbitrarily set as
one). (B) c-Jun
2/2 MEFs were treated in the presence or absence
of 10 IU IFNb for 24 h, cell lysates were prepared, and expression
of STAT1 was assessed by Western blot. (C) Wild-type MEFs were
treated in the presence or absence of various doses of IFNb for 24
h, RNA was isolated, and expression of STAT1 was assessed by
qRT-PCR. Histograms represent mean and error bars the SEM of
three independent experiments (arbitrarily set as one).
Found at: doi:10.1371/journal.pbio.1000361.s002 (0.81 MB TIF)
Figure S3 Expression of STAT1, 2, and 3 in IFNAR1
knockout cells. (A) The expression of STAT2 mRNA (top
panel) and STAT3 protein (bottom panel) was determined in wild-
type and IFNAR1
2/2 MEFs by QRT-PCR and Western blotting,
respectively. (B) Wild-type, IFNAR1
2/2,o rc-Jun
2/2 MEFs were
cultured in fresh media (white bars) or conditioned media from
wild-type MEFs (black bars) for 16 h. RNA was extracted, cDNA
synthesized, and STAT1 mRNA expression assessed by qRT-
PCR. STAT1 mRNA expression was normalized to that of
untreated IFNAR1
2/2 MEFs cultured in fresh media. Data are
representative of three similar experiments.
Found at: doi:10.1371/journal.pbio.1000361.s003 (0.65 MB TIF)
Figure S4 Reconstitution of STAT1 in IFNAR1 knockout
cells restores IFNc-mediated upregulation of IFN re-
sponse genes. Wild-type MEFs, IFNAR1
2/2 MEFs, and
IFNAR1
2/2 MEFs transduced with empty vector (IFNAR1
2/2
MSCV) or IFNAR1
2/2 MEFs transduced with HA-tagged
STAT1a (IFNAR1
2/2 STAT1) were treated with 100 IU/mL
IFNc for 0, 1, or 6 h. RNA was extracted, cDNA synthesized, and
qRT-PCR performed with primers specific for caspase 4 (CASP 4),
CISH, CXCL11, and MYD88. mRNA levels are expressed relative
to those of wild-type C57/BL6 (B6) splenocytes. Histograms
represent the mean and error bars the standard error of four
independent experiments (* p,0.05 for samples that were
significantly induced).
Found at: doi:10.1371/journal.pbio.1000361.s004 (1.56 MB TIF)
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